JP2024540241A - 治療上の使用のためのアンブロキソールの修飾形態 - Google Patents

治療上の使用のためのアンブロキソールの修飾形態 Download PDF

Info

Publication number
JP2024540241A
JP2024540241A JP2024525932A JP2024525932A JP2024540241A JP 2024540241 A JP2024540241 A JP 2024540241A JP 2024525932 A JP2024525932 A JP 2024525932A JP 2024525932 A JP2024525932 A JP 2024525932A JP 2024540241 A JP2024540241 A JP 2024540241A
Authority
JP
Japan
Prior art keywords
compound
day
ambroxol
disease
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540241A5 (enExample
Inventor
スティーブン アンダーソン,
スティーブン パステルナーク,
ヴィンセント ジャック,
ジェラルド ブラッサード,
Original Assignee
ザイウィー, エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザイウィー, エルエルシー filed Critical ザイウィー, エルエルシー
Publication of JP2024540241A publication Critical patent/JP2024540241A/ja
Publication of JP2024540241A5 publication Critical patent/JP2024540241A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/44—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/70—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024525932A 2021-10-28 2022-10-27 治療上の使用のためのアンブロキソールの修飾形態 Pending JP2024540241A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272743P 2021-10-28 2021-10-28
US63/272,743 2021-10-28
PCT/US2022/078779 WO2023076997A1 (en) 2021-10-28 2022-10-27 Modified forms of ambroxol for therapeutic use

Publications (2)

Publication Number Publication Date
JP2024540241A true JP2024540241A (ja) 2024-10-31
JP2024540241A5 JP2024540241A5 (enExample) 2025-11-04

Family

ID=84364209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525932A Pending JP2024540241A (ja) 2021-10-28 2022-10-27 治療上の使用のためのアンブロキソールの修飾形態

Country Status (7)

Country Link
US (1) US20250235413A1 (enExample)
EP (1) EP4423041A1 (enExample)
JP (1) JP2024540241A (enExample)
KR (1) KR20240095271A (enExample)
CN (1) CN118660866A (enExample)
CA (1) CA3235692A1 (enExample)
WO (1) WO2023076997A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506236A (ja) * 2017-02-07 2020-02-27 エスティーシー. ユーエヌエムStc.Unm 長期間持続するオートファジー誘発のための同位体増強アンブロキソール
CN114907221A (zh) * 2021-02-06 2022-08-16 华创合成制药股份有限公司 一种氘代氨溴索衍生物及其制备和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5354566A (en) 1993-06-02 1994-10-11 Kraft General Foods, Inc. Preparation of yeast-leavened dough crusts
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
IL160539A0 (en) 2001-09-04 2004-07-25 Boehringer Ingelheim Int Anti-influenzal agents
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
DE10332487A1 (de) 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506236A (ja) * 2017-02-07 2020-02-27 エスティーシー. ユーエヌエムStc.Unm 長期間持続するオートファジー誘発のための同位体増強アンブロキソール
CN114907221A (zh) * 2021-02-06 2022-08-16 华创合成制药股份有限公司 一种氘代氨溴索衍生物及其制备和用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
REGISTRY(STN)[ONLINE], JPN7026003334, 13 September 2011 (2011-09-13), ISSN: 0005915095 *
REGISTRY(STN)[ONLINE], JPN7026003335, 22 August 2010 (2010-08-22), ISSN: 0005915096 *
REGISTRY(STN)[ONLINE], JPN7026003336, 9 April 2010 (2010-04-09), ISSN: 0005915097 *
公益社団法人 日本化学会, 化学便覧 応用化学編 第7版, JPN6022021402, 2014, pages 252 - 253, ISSN: 0005915099 *
化学と教育, vol. 61, no. 8, JPN6022001268, 2013, pages 404 - 407, ISSN: 0005915098 *

Also Published As

Publication number Publication date
WO2023076997A1 (en) 2023-05-04
CA3235692A1 (en) 2023-05-04
EP4423041A1 (en) 2024-09-04
US20250235413A1 (en) 2025-07-24
CN118660866A (zh) 2024-09-17
KR20240095271A (ko) 2024-06-25

Similar Documents

Publication Publication Date Title
JP7069253B2 (ja) 統合失調症を治療するための2-((1-(2(4-フルオロフェニル)-2-オキソエチル)ピペリジン-4-イル)メチル)イソインドリン-1-オン
JP6395838B2 (ja) 神経疾患の処置のためのトラセミド及びバクロフェンを含む組成物
US11484530B2 (en) Pharmaceutical compositions comprising the PPAR agonist INT-131 and Nrf2 activators
US11278531B2 (en) Combination of ibudilast and riluzole and methods of using same
TW201629004A (zh) 酚系trpv1促效劑之前藥
EP3654960A1 (en) Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity
CN111556750A (zh) 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途
JP2016508489A (ja) プロトパナキサジオール誘導体、その製造方法及びその応用
US20250235413A1 (en) Modified forms of ambroxol for therapeutic use
US20250011277A1 (en) Modified forms of ambroxol for therapeutic use
HK1245081A1 (zh) 用於治疗阿尔茨海默病的方法
US20150366847A1 (en) Combination of geranylgeranylacetone and ibudilast and methods of using same
JP7599664B2 (ja) 精神障害性疾患を予防および治療するための化合物およびその適用
JP2021524853A (ja) ハンチントン病を治療するのに使用するための薬学的化合物
WO2025042610A1 (en) Pifithrin analogues and methods of treating rett syndrome
KR20250047213A (ko) 질소 함유 헤테로고리 화합물의 다형체 및 그의 용도
WO2016086000A1 (en) A combination of geranygeranylacetone, ibudilast, and riluzole and methods of using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260723

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260724